CTXR 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

CTXR ▲ +0.87% at T+20d

SHORT call ✗ call lost -0.87% · α vs SPY +4.09% · entry $0.6910 → $0.6970

Next anchor: T+60d in 6w

Currently $0.5559 · +19.55% from $0.6910 entry (call sign-flipped)

Entry anchored
Apr 24, 03:59 PM ET
via Databento tick

T+1d

-5.93%

call +5.93% · α +5.45%

$0.6500

settled 6w ago

T+5d

+2.75%

call -2.75% · α -2.35%

$0.7100

settled 6w ago

T+20d

+0.87%

call -0.87% · α +4.09%

$0.6970

settled 19d ago

T+60d

—

call — · α —

—

in 6w

Price Chart

Loading chart...

Executive Summary

Citius Pharmaceuticals entered into a securities purchase agreement to raise $5 million through a registered direct offering of common shares and pre-funded warrants, accompanied by concurrent private placement of warrants. This capital raise, disclosed in an 8-K filing, is intended to fund the commercialization of LYMPHIR and development of other product candidates. The offering was completed within one day of the prior 424B5 filing, confirming immediate execution.

Key Financial Metrics

Deal Value

$5.0M

Actionable Insight

Monitor for potential downward pressure on the stock price due to share dilution from the capital raise, especially given the company's small $21M market cap. The funding provides runway for LYMPHIR commercialization, but investors should watch for execution risks in bringing the product to market.

Key Facts

Citius Pharmaceuticals raised $5 million through a registered direct offering
The offering included 4.73 million common shares and pre-funded warrants for 345,686 shares at $0.985 per share
Concurrent private placement of warrants was also completed
Net proceeds of $4.5 million will fund LYMPHIR commercialization and other product development
The offering was completed on April 24, 2026, immediately following the 424B5 filing

Financial Impact

The company raised $5 million in gross proceeds through the issuance of common shares and pre-funded warrants at $0.985 per share, with net proceeds of $4.5 million after expenses

cashdilutionequity

Risk Factors

Significant share dilution from issuing over 5 million shares and warrants
Execution risk in commercializing LYMPHIR despite new funding
Potential downward price pressure from investor selling after the offering

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

75% bullish (8 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001213900-26-047599
Document: ea028762001ex4-3.htm	0001213900-26-047599
Document: ea028762001ex4-1.htm	0001213900-26-047599
Document: ea028762001ex4-2.htm	0001213900-26-047599

6 reports for CTXR

T+1T+5T+20T+60

50% Hit rate 2 of 4 directional calls best @ T+5▲ +13.49%May 22, 2026

Filters

Reports for CTXR — sortable, filterable
	Type				Now
Jun 3, 2026 6d ago	EFFECT BEARISH ★ 6/10	$0.5800 $0.5900	▼ −1.72%	▼ −1.33%	$0.5559 (+4.16%)
Jun 1, 2026 8d ago	8-K NEUTRAL ★ 4/10	$0.6030 $0.5800	▼ −3.81%	▼ −3.09%	$0.5559 (−7.81%)
May 22, 2026 18d ago	S-3 BEARISH ★ 6/10	$0.6970 $0.6900	▲ +1.00%	▲ +1.02%	$0.5559 (+20.24%)
May 15, 2026 25d ago	8-K BEARISH ★ 6/10	$0.5270 $0.5540	▼ −5.12%	▼ −5.77%	$0.5559 (−5.48%)
Apr 24, 2026 6w ago	8-K BEARISH ★ 6/10	$0.6910 $0.6500	▲ +5.93%	▲ +5.45%	$0.5559 (+19.55%)
Apr 24, 2026 6w ago	424B5 BEARISH ★ 6/10	$0.7700 $0.6910	▲ +10.26%	▲ +10.42%	$0.5559 (+27.81%)

US Market Status

Market Closed — Opens Thu (11h 12m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access